{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=40",
    "query": {
      "condition": "Kidney (Renal Cell) Cancer",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 1535,
    "total_pages": 154,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T14:12:13.637Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01108445",
      "title": "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01108445"
    },
    {
      "nct_id": "NCT03528057",
      "title": "Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Robotic-Assisted Laparoscopic Partial Nephrectomy",
        "Hemostatic Agents",
        "Renal Malignant Tumor"
      ],
      "interventions": [
        {
          "name": "Hemostat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-04-18",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03528057"
    },
    {
      "nct_id": "NCT00278395",
      "title": "Vorinostat in Treating Patients With Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2005-10",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278395"
    },
    {
      "nct_id": "NCT00854620",
      "title": "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Kidney Disease",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2007-12",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-06-19",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00854620"
    },
    {
      "nct_id": "NCT00849186",
      "title": "Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2015-02-06",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849186"
    },
    {
      "nct_id": "NCT00005958",
      "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Sacramento, California • Washington D.C., District of Columbia + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Gurnee",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005958"
    },
    {
      "nct_id": "NCT00429026",
      "title": "Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-01",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00429026"
    },
    {
      "nct_id": "NCT01689662",
      "title": "Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tc 99m EC20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endocyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2002-08",
      "completion_date": "2003-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01689662"
    },
    {
      "nct_id": "NCT05534620",
      "title": "Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukaemia (AML)",
        "Myelodysplastic Syndrome (MDS)",
        "Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)"
      ],
      "interventions": [
        {
          "name": "Treosulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "medac GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-02-01",
      "completion_date": "2025-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Columbus, Ohio • Richmond, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05534620"
    },
    {
      "nct_id": "NCT05769959",
      "title": "Study of RO7515629 in Participants With HLA-G Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "RO7515629",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2023-06-15",
      "completion_date": "2024-03-19",
      "has_results": false,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-18T14:12:13.637Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05769959"
    }
  ]
}